**Impaired Lymphocyte Responses in Pediatric Sepsis Vary by Pathogen Type**

Robert B. Lindell MD, Donglan Zhang, Jenny Bush RNC, Douglas C. Wallace PhD, Joshua D. Rabinowitz MD PhD, Wenyun Lu PhD, E. John Wherry PhD, Scott L. Weiss MD MSCE, Sarah E. Henrickson MD PhD

**ONLINE REPOSITORY**

**ONLINE REPOSITORY TEXT (LIMITED TO METHODS ONLY)**

Study Design and Population

The study was approved by the Children’s Hospital of Philadelphia Institutional Review Board, and written informed consent was obtained prior to any study procedures. We performed a prospective observational study of patients less than 18 years treated for severe sepsis or septic shock in a single academic PICU between May 2014 and June 2018. Severe sepsis and septic shock were defined using consensus pediatric criteria (1). Exclusion criteria were weight less than 7.5kg (due to limits on blood collection), WBCs less than 0.5 ×103/μL, known mitochondrial disease, unrepaired cyanotic heart disease, and prior study enrollment. A convenience sample of postoperative neurosurgical patients without evidence for infection or organ dysfunction were enrolled as controls.

Clinical Data Collection

Clinical data related to patient characteristics, therapies, and vital status were abstracted from each study participant. Organ dysfunction, as previously defined, was monitored for 28 days after sepsis recognition. Severity of illness was assessed by the Pediatric Index of Mortality-2 (PIM-2) score (2), Pediatric Risk of Mortality-III (PRISM-III) score (3), and Pediatric Logistic Organ Dysfunction (PELOD) score (4). Exposure to endotracheal intubation and mechanical ventilation were obtained from clinical flowsheets and physician documentation. Exposure to vasopressor infusion and steroids were obtained from the medication administration record.

Biospecimen Collection

A day 1-2 sample of 7-9ml of blood was collected as soon as possible after consent and enrollment. For patients with sepsis, additional blood was collected between study days 3-5 (and at least 2 days after first sample) and again between days 8-14 for patients who remained in the PICU. For control patients, a single sample was drawn on the date of consent and enrollment. Blood was collected in citrate tubes for measurement of mitochondrial respiration, EDTA tubes for monocyte human leukocyte antigen DR (HLA-DR) expression (mHLA-DR), and lithium heparin tubes (on ice) for measurement of whole-blood *ex vivo* LPS-induced tumor necrosis factor-alpha (TNF-a) and cytokine analyses. Mitochondrial respiration, monocyte HLA-DR, and *ex vivo* LPS-stimulated TNF-a were measured on fresh blood samples. Additional peripheral blood mononuclear cells (PBMCs) and heparin plasma were isolated by density gradient centrifugation and cryopreserved at -80 degrees C for subsequent analysis.

Flow Cytometry

Cryopreserved PBMCs were partially thawed in a 37 degree C water bath, then resuspended in warm complete medium and plated into a 96-well round-bottom plate at a concentration of 1 x106 PBMCs per well. For general immune profiling, cells were incubated with a cocktail of antibodies targeting surface proteins at room temperature for 30 minutes and then washed. After fixation and permeabilization, cells were incubated with a cocktail of antibodies targeting intracellular proteins at room temperature for 60 minutes and then washed. After staining, cells were resuspended into 1.6% PFA fixative and held overnight at 4 degrees C prior to acquisition. For analysis of intracellular cytokines, PBMCs were stimulated with PMA/ionomycin for 4 hours prior to surface and intracellular staining per the above protocol.

Surface and intracellular antibodies used for this study are detailed in Table E1.

Cells were analyzed on a LSR II flow cytometer (BD Biosciences, San Jose, CA) according to the manufacturer protocol. Single stain controls were performed with compensation beads (UltraComp Beads, Invitrogen/ThermoFisher Scientific, Waltham, MA). Compensated FCS files were then loaded into FlowJo (Tree Star, Ashland, OR) for predefined analysis of immune cell subsets. After identification of live singlet CD3+ lymphocytes, populations of CD4+ and CD8+ lymphocytes were identified through bivariate plots. Subsets of CD4+ and CD8+ cells were analyzed by CD45RA and CD27 expression using the following definitions: naïve T cell (CD45RA+/CD27+), central memory T cell (CD45RA-/CD27+), effector memory T cell (CD45RA-/CD27-), and TEMRA cell (CD45RA+/CD27-) which are a subset of effector memory cells which re-express CD45RA. Non-naïve CD4+ and CD8+ T cells were defined as the union of central memory T cells, effector memory T cells, and TEMRA cells.

We then assessed CD4+ T cell differentiation by measuring intracellular cytokines via flow cytometry after PMA/ionomycin stimulation. After defining non-naïve T cells using the lineage markers and gating strategy above, we identified CD4+ T cell states based on intracellular cytokine expression: Th1 (IFN-g+), Th2 (IL13+), Th17 (IL-17a+), Tfh (IL-21+), and Treg (FoxP3+). Finally, in this group we defined the activation state of these CD4+ T cell subsets by defining the IL-2+ and CD38+ cells within groups.

Mitochondrial Bioenergetics

Mitochondrial respiration was measured in PBMCs isolated from citrated whole blood by density gradient centrifugation as previously described (5). PBMC cell counts were performed using trypan blue exclusion (Countess II, Life Technologies, Grand Island, NY) with median viability 88% (interquartile range 76-95%). After isolation, the PBMC pellet was re-suspended in Hank’s balanced salt solution (pH 7.40) containing 5.5 mM glucose, 1mM pyruvate, and 10 mM HEPES, centrifuged a final time at 100g for 10 minutes at 20°C, and then again re-suspended in the same “respiration buffer”. Mitochondrial respiration was measured in 2-4 x 106 intact PBMCs at 37°C using a high-resolution oxygraph (Oxygraph-2k Oroboros Instruments, Innsbruck, Austria). Oxygen flux (in pmol O2/sec/106 cells), which is directly proportional to oxygen consumption (respiration), was recorded continuously using DatLab software 4.3 (Oroborus Instruments, Innsbruck, Austria) as shown below and as previously described (5, 6). Intact cells were utilized to maintain the cellular microenvironment such that respiration relied on endogenous substrates. After routine oxygen consumption was recorded for 10-20 minutes, the ATP-synthase inhibitor oligomycin (1 μg/mL) was added to induce a state 4-like respiration independent of mitochondrial ATP production. Under these conditions, respiration was primarily due to leakage of protons across the inner mitochondrial membrane (LEAK). Routine minus LEAK indicated ATP-linked respiration. Maximal oxygen consumption through the electron transport system (ETS) was obtained by stepwise titration (1-2 μM) of the uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) until no further increase in oxygen consumption was detected (ETSmax). The ETSmax indicates the maximal oxygen consumption possible through the electron transport system after pharmacologically uncoupling oxygen utilization from ATP production to assess the integrity of the ETS independent of energy production. Therefore, ETSmax reflects only the ability the ETS to use electrons to reduce oxygen to water without the need to add high-energy phosphate bonds to produce ATP, a final step in the energy-production pathway that normally helps to regulate ETS activity. Mitochondrial respiration was then inhibited by adding the ETS complex IV inhibitor, sodium azide, in 5-10 mM increments, followed by the ETS complex III inhibitor, antimycin A, in 5 μL increments until no further decrease in oxygen consumption was observed. The residual oxygen flux reflective of non-mitochondrial respiration was subtracted from other respiration values. Respiration supporting mitochondrial ATP synthesis (ATP-linked respiration) was calculated as routine minus LEAK respiration. Spare respiratory capacity (SRC), calculated as ETSmax minus routine respiration, is the mitochondrial bioenergetic reserve available for cells to produce ATP in response to a stress-induced increase in metabolic demand.

Functional Assays

*Ex vivo* LPS-stimulated whole blood TNF-a was measured by mixing 50ml heparinized whole blood with 500ml (250 pg) of phenol-extracted LPS from *Salmonella enterica abortus equi* (Sigma-Aldrich, L5886) within 60 to 90 minutes of blood collection as previously described (7). The sample was then incubated for 4 hours at 37 degrees C, followed by centrifugation at 1,000 g for 5 minutes. The supernatant was stored at -80 degrees C for batched analysis. TNF-a was measured, in duplicate, using an enzyme-linked immunosorbent assay kit (Invitrogen KHC3011C). Immunoparalysis was *a priori* defined as LPS-stimulated TNF-a less than 200pg/ml. Monocyte HLA-DR was measured using a whole-blood lysis technique. The sample was then stained with labeled anti-HLA-DR and anti-CD14 antibodies and the percentage of HLA-DR-positive cells among the CD-14 positive population was determined using flow cytometry.

Plasma Proteomics

Interleukin (IL)-4, IL-6, IL-10, IL-18, IL-1RA, and Interferon (IFN)-g were measured using commercially available assays (Cytokine Human Magnetic 30-Plex Panel, Invitrogen/ThermoFisher Scientific, Waltham, MA; Human Magnetic Luminex Assay and CRP DuoSet ELISA, R&D Systems, Minneapolis, MN). All samples were run in duplicate. FLUOstar software® (Ortenberg, Germany) was used to calculate standard curves for each analyte. To ensure accuracy and precision, the standard curve was required to have r2 >95%, and the results from mock samples were required to be within the 95% confidence interval of the expected range provided by the manufacturer.

Plasma Metabolomics

Water-soluble plasma metabolites were analyzed by liquid chromatography-mass spectrometry, using the protocol previously described by Lu et al (8). Briefly, 200ml ice-cold methanol was added to each 50μl plasma sample, vortexed for 10 seconds and then transferred to a -20 degree C for 20 minutes. Samples were centrifuged at 13,200rpm for 15 minutes. The supernatant was extracted and then dried under nitrogen flow and reconstituted in 1ml LC-MS grade water. Samples were analyzed on two separate instrument platforms to cover both positive charged and negative charged metabolites.

Negative charged metabolites were analyzed via reverse-phase ion-pairing chromatography coupled to an Exactive orbitrap mass spectrometer (ThermoFisher Scientific, San Jose, CA). The mass spectrometer was operated in negative ion mode with resolving power of 100,000 at m/z 200, scanning range being m/z 75-1000. The LC separation was achieved using a Synergy Hydro-RP column (100mm × 2 mm, 2.5 µm particle size, Phenomenex, Torrance, CA) with a flow rate of 200 µL/min. The LC gradient was 0 min, 0% B; 2.5 min, 0% B; 5 min, 20% B; 7.5 min, 20% B; 13 min, 55% B; 15.5 min, 95% B; 18.5 min, 95% B; 19 min, 0% B; 25 min, 0% B. Solvent A is 97:3 water:methanol with 10 mM tributylamine and 15 mM acetic acid; solvent B is methanol.

Positive charged metabolites were analyzed on a Q Exactive Plus mass spectrometer coupled to Vanquish UHPLC system (ThermoFisher Scientific, San Jose, CA). The mass spectrometer was operated in positive ion mode with resolving power of 140,000 at m/z 200, scanning range being m/z 75- 1000. The LC separation was achieved on an Agilent Poroshell 120 Bonus-RP column (150 x 2.1 mm, 2.7 µm particle size). The gradient was 0 min, 50 µL/min, 0.0%B; 6 min, 50 µL/min, 0% B; 12 min, 200 µL/min, 70% B; 14 min, 200 µL/min, 100 %B; 18 min, 200 µL/min, 100% B; 19 min, 200 µL/min, 0% B; 24 min, 200 µL/min, 0% B; 25 min, 50 µL/min, 0% B. Solvent A is 10mM ammonium acetate + 0.1% acetic acid in 98:2 water:acetonitrile and solvent B is acetonitrile.

For each sample, ion-specific chromatograms for metabolites of interest were identified, and ion counts were abstracted for further analysis. The following metabolites were analyzed in this exploratory analysis: (iso)leucine, alanine, arginine, aspartate, citrate, citrulline, glucosamine, glutamine, histidine, hypoxanthine, lactate, lysine, methionine, phenylalanine, proline, taurine, threonine, valine, 2-dehydrogluconate, 2-hydroxy-glutarate, acetyl-glycine, a-ketoglutarate, allantoin, asparagine, cystathionine, cysteine, D-glucarate, D-gluconate, fumarate, gluconolactone, glutamate, glycine, glycolate, hippuric acid, homocysteine/ methylcysteine, hydroxyphenylpyruvate, hydroxyproline, indolelactic acid, inosine, kynurenine, malate, N-acetyl-L-alanine, N-acetyl-L-ornithine, phenyllactic acid, pyruvate, serine, trehalose, tyrosine, uric acid, uridine, and xanthine.

Statistical Analyses

Manual flow cytometry gating was completed in FlowJo (9) as detailed above. Data processing and analyses were completed in R Studio (10). Extraction and computation was facilitated with the ‘dplyr’ package. Graphs were plotted with the ‘ggplot2’ and ‘ggpubr’ packages. All remaining source code was custom developed. Data are presented as median with interquartile range (IQR) for continuous variables and counts with percentages for categorical variables. Correlation coefficients were quantified by the Spearman rank correlation coefficient. Tests of association between continuous versus categorical variables were performed by unpaired Wilcoxon test or Kruskal-Wallis test as appropriate. Association between categorical variables was assessed by Fisher’s exact test. All tests were performed in a two-sided manner, using a nominal significance threshold of *p* < 0.05 unless otherwise specified, with Bonferroni corrections for analyses that included multiple comparisons.

**REFERENCES**

1. Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric S. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6(1):2-8.

2. Slater A, Shann F, Pearson G, Paediatric Index of Mortality Study G. PIM2: a revised version of the Paediatric Index of Mortality. Intensive Care Med. 2003;29(2):278-85.

3. Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med. 1996;24(5):743-52.

4. Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, et al. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study. Lancet. 2003;362(9379):192-7.

5. Weiss SL, Selak MA, Tuluc F, Perales Villarroel J, Nadkarni VM, Deutschman CS, et al. Mitochondrial dysfunction in peripheral blood mononuclear cells in pediatric septic shock. Pediatr Crit Care Med. 2015;16(1):e4-e12.

6. Pesta D, Gaiger E. High-Resolution Respirometry: OXPHOS Protocols for Human Cells and Permeabilized Fibers form Small Biopsies of Human Muscle. In: AJ PCaM, editor. Mitochochondrial Bioenergetics: Methods and Protocols. 810: Springer Science+Business Media; 2012. p. 25-58.

7. Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk HD, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 2011;37(3):525-32.

8. Lu W, Clasquin MF, Melamud E, Amador-Noguez D, Caudy AA, Rabinowitz JD. Metabolomic analysis via reversed-phase ion-pairing liquid chromatography coupled to a stand alone orbitrap mass spectrometer. Anal Chem. 2010;82(8):3212-21.

9. FlowJo Software v10.8. Ashland, OR: Becton, Dickinson and Company; 2021.

10. RStudio Team. RStudio: Integrated Development for R. Boston, MA: RStudio, PBC; 2020.**TABLES**

**Table E1.** Antibodies used in flow cytometry panels.

|  |  |  |  |
| --- | --- | --- | --- |
| Marker | Fluorophore | Clone | Vendor |
| IL-2 | BV 421 | 5344.111 | BD |
| Live/Dead | L/D Aqua | N/A | Invitrogen |
| CD14+16+19 | V500 | M5E2, 3G8, HIB19 | BD |
| CD3 | QD 585 | OKT3 | Custom-conjugated |
| CD45RA | BV 605 | HI100 | BioLegend |
| CD8 | SB 645 | RPA-T8 | Invitrogen |
| PD-1 | BV 711 | EH12.1 | BD |
| CD27 | BV 785 | O323 | BioLegend |
| IL-21 | AF 647 | 3A3-N2 | BioLegend |
| Foxp3 | A700 | PCH101 | Invitrogen |
| IL-17a | APC-Cy7 | BL168 | BioLegend |
| IL-10 | AF 488 | JES3-9D7 | BioLegend |
| IL-13 | PE | JES10-5A2 | Invitrogen |
| CD38 | PE-Texas Red | HIT2 | Life Technologies |
| CD4 | PE-Cy5.5 | SK3 | Invitrogen |
| IFN-γ | PE-Cy7 | B27 | BioLegend |